Insider selling
Traded Nov 18 · filed 1 day laterNot reported under a pre-arranged trading plan
Since the trade −1.7% · S&P 500 −5.5% · to Nov 20
BioMarin Pharmaceutical's Chief R&D Officer sold $303K of BioMarin Pharmaceutical shares. The filing does not indicate a pre-arranged trading plan.